Physician profile
Timothy B Cavanaugh
NPI 1083686729
$4,590.85
in general payments reported to CMS, 2019-2025
28 companies · $464 in 2025
The $464 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $936 · 2020: $532 · 2021: $536 · 2022: $942 · 2023: $721 · 2024: $460 · 2025: $464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,645.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,644.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,664.00 | 2019-2025 | Clareon, Clareon Panoptix Pro, Argos |
| Allergan, INC. | $373.84 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $302.04 | 2019-2025 | Cequa |
| Glaukos Corporation | $272.59 | 2020-2025 | Kxl System (Not Refurbished), Ce-Marked Kxla System, Kxl1b-Ce-Marked Kxlsystem |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $207.06 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $185.50 | 2022-2025 | Vyzulta, Xiidra, Lotemax Sm |
| Oyster Point Pharma, INC. | $174.74 | 2022-2025 | Tyrvaya, Ryzumvi |
| Dompe US, INC. | $167.67 | 2019-2025 | Oxervate |
| Johnson & Johnson Surgical Vision, INC. | $157.77 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $145.18 | 2022 | |
| Avedro INC. | $126.30 | 2019 | |
| Kala Pharmaceuticals, INC. | $116.44 | 2019-2022 | |
| Abbvie INC. | $83.70 | 2022-2023 | Alphagan P, Lumigan, Vuity |
| Viiv Healthcare Company | $82.37 | 2020-2022 | |
| Rxsight INC | $80.41 | 2024 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $73.08 | 2022 | |
| Ocular Therapeutix, INC. | $64.67 | 2021-2024 | Dextenza |
| Biotissue Holdings INC. | $59.72 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $53.88 | 2020-2021 | |
| Eyevance Pharmaceuticals LLC | $36.07 | 2022 | |
| Beaver-Visitec International, INC. | $31.08 | 2022 | |
| Shire North American Group INC | $22.93 | 2019 | |
| Lombart Brothers, INC. | $22.22 | 2025 | Opd-III |
| Tarsus Pharmaceuticals, INC. | $20.69 | 2025 | Xdemvy |
| Mallinckrodt Enterprises LLC | $20.38 | 2019 | |
| Thea Pharma INC. | $17.50 | 2022 | |
| Alcon Research LLC | $15.07 | 2019 | |
| Staar Surgical Company | $13.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Cavanaugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.